Roquefort Therapeutics (LON:ROQ) Stock Price Down 8.9% – Time to Sell?

Roquefort Therapeutics plc (LON:ROQ) shares fell 8.9% during trading on Wednesday . The stock traded as low as GBX 2 ($0.03) and last traded at GBX 2.01 ($0.03). 1,972,329 shares changed hands during trading, a decline of 40% from the average session volume of 3,297,688 shares. The stock had previously closed at GBX 2.20 ($0.03).

Roquefort Therapeutics Stock Performance

The company has a debt-to-equity ratio of 12.37, a current ratio of 0.79 and a quick ratio of 3.07. The company has a market cap of £2.66 million, a PE ratio of -1.73 and a beta of 0.05. The stock has a 50 day simple moving average of GBX 2.66 and a two-hundred day simple moving average of GBX 3.55.

Insider Activity at Roquefort Therapeutics

In related news, insider Stephen Paul West purchased 400,000 shares of the stock in a transaction that occurred on Tuesday, February 4th. The shares were purchased at an average price of GBX 3 ($0.04) per share, with a total value of £12,000 ($15,560.17). 60.40% of the stock is owned by insiders.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.